A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Swedish Orphan Biovitrum
- Study ID
- NCT06782373
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- VEXAS
- VEXAS Syndrome
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pacritinib — DRUGSupplied in hard capsules.
- Placebo — DRUGSupplied in hard capsules.
Study Details
This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. 78 participants will be enrolled, randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. Randomization will be stratified by prescribed GC dose on the day of randomization.
Key Dates
- Start date
- May 28, 2025
- Status verified
- Mar 2026
- Primary completion
- Dec 30, 2026
- Completion
- May 22, 2028
Study Design
- Enrollment
- 78 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: PacritinibTo receive oral administration of pacritinib dose A for up to 24 weeks.
- Experimental: Pacritinib + placeboTo receive oral administration of pacritinib dose B plus placebo for up to 24 weeks
- Placebo Comparator: PlaceboTo receive oral administration of placebo for up to 24 weeks.
Primary Outcome Measure
Overall Clinical Response (OCR), defined as achieving Clinical Response or better at any time during the double-blind treatment period. [ Time Frame: up to End of Week 24 ]
Central Contacts
- Study Physician+4686972000
Locations (9)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic - Scottsdale | Scottsdale | Arizona | 85259 | - |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | - |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | - |
| NYU Langone Health | New York | New York | 10016 | - |
| Cleveland Clinic - Cleveland | Cleveland | Ohio | 44195 | - |
| The James Cancer Hospital and Solove Research Institute | Columbus | Ohio | 43210 | - |
| UT MD Anderson Cancer Center | Houston | Texas | 77030 | - |
| University of Utah Healthcare | Salt Lake City | Utah | 84132 | - |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | - |
Find similar trials in Scottsdale, AZ
Related Studies
- Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) SyndromePHASE1 · Recruiting · Washington University School of Medicine · St Louis, Missouri
- Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research StudyEnrolling By Invitation · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland